The S&P/ASX 200 Index (ASX: XJO) is climbing higher this week. Since yesterday morning, the index has gained 0.8% and is now 1.86% higher for the year to date.
But some shares are expected to far outpace the index this year. Here are three ASX 200 shares I have my eye on, and analysts are tipping upside of 50% to 60% each!
Image source: Getty Images
Aristocrat Leisure Ltd (ASX: ALL)
Aristocrat is an Australian gaming technology company licensed in around 340 gaming jurisdictions in more than 100 countries.
Its shares are trading in the green on Tuesday afternoon. At the time of writing, the shares are up 0.58% to $52.31. For the year to date, the shares are 8.61% lower, and they're down 29.25% on the year.
The gaming company has suffered headwinds from a strengthening Australian dollar this year, but analysts are confident that the business has some great growth prospects ahead.
Analysts are optimistic that the ASX 200 stock can turn its shares around over the next 12 months.
Data shows a buy consensus among analysts, with a maximum upside of $82.20 per share, implying a potential 56.98% upside at the time of writing.
CAR Group Ltd (ASX: CAR)
CAR is a global digital marketplace business, headquartered in Australia. It operates well-known automotive websites like carsales, Encar, and Trader Interactive.
The company posted solid revenue and earnings growth in its FY26 half-year result, and reaffirmed its full-year guidance. But a wider market sell-off and overall sector weakness have pushed the stock lower through the first month of 2026.
At the time of writing, the shares are 1.93% higher at $27.43 each. For the year to date, they've fallen 11.14% and they're now a huge 28.49% lower than this time last year.
But analysts are very optimistic that the share price will see a strong push over the next 12 months. The maximum target price is $42.20, which implies a potential 53.79% upside at the time of writing.
Ebos Group Ltd (ASX: EBO)
Ebos is the largest pharmaceutical wholesaler and distributor across Australia, New Zealand, and Southeast Asia. The company provides pharmaceutical and wellness products to community pharmacies, public and private hospitals, day surgeries, general practices, aged care facilities, and specialist clinics.
The company is a fairly new player on the ASX 200, after its shares entered the index on the 22nd of September. In August last year, the ASX 200 healthcare stock crashed 14% to a 4-year low after investors were spooked by declines posted in its FY25 results.
Since entering the index in September, its shares have tumbled another 14%. At the time of writing, the shares are up 0.37% to $21.98 a piece.
But now, some analysts see the oversold stock as severely undervalued.
Data shows that five out of 9 analysts have a buy or strong buy rating on Ebos shares. Another two have a hold rating, and two have a sell rating. The maximum target price is $34.82, which implies a 58.34% upside at the time of writing.
